认知储备对显性遗传性阿尔茨海默病症状起病年龄及认知衰退的影响
本研究基于显性遗传性阿尔茨海默病网络(DIAN)710名参与者的数据,采用残差潜变量法将认知表现分解为人口学、生物标志物和储备成分。结果显示,在无症状携带者中,储备成分每增加1个标准差,临床未受损(CDR-SB=0)的比值增加4.06倍(95%CI 1.84-8.95);在有症状携带者中,储备成分每增加1个标准差与基线CDR-SB评分降低0.81倍相关(95%CI 0.72-0.92)。提示较高认知储备与延迟转化为轻度认知障碍及减缓临床痴呆评定量表进展相关。
要点
- 在无症状DIAD携带者中,认知储备成分每升高1 SD,临床未受损的比值增加4.06倍。
- 在有症状DIAD携带者中,认知储备成分每升高1 SD与基线CDR-SB降低0.81倍相关。
- 认知储备对遗传决定的AD临床轨迹具有保护性修饰作用。
核心结论
- 较高认知储备值与延迟转化为轻度认知障碍及减缓临床痴呆评定量表进展相关。
- 认知储备可能在遗传决定的阿尔茨海默病临床轨迹中起保护性修饰作用。
研究设计与样本
- 研究分析了显性遗传性阿尔茨海默病网络(DIAN)研究的710名参与者,包括271名非DIAD携带者、284名无症状DIAD携带者和155名有症状DIAD携带者。
- 认知储备采用基于残差的潜变量方法建模,分解为人口学(CogD)、生物标志物(CogB)和储备或残差(CogR)成分。
- 主要结局为临床症状起病年龄(CDR>0)和临床痴呆评定量表-总和框(CDR-SB)的纵向变化,使用Cox比例风险模型和线性混合效应模型分析,并校正估计发病年数(EYO)。
主要发现
- 在无症状携带者中,采用校正EYO的零膨胀模型显示,储备成分(CogR)每增加1个标准差,临床未受损(CDR-SB=0)的比值增加4.06倍(95%CI 1.84-8.95)。
- 人口学成分(CogD)每增加1个标准差,CDR-SB=0的比值增加2.60倍(95%CI 1.10-6.16);生物标志物成分(CogB)每增加1个标准差,CDR-SB=0的比值增加5.16倍(95%CI 2.00-13.33)。
- 在有症状携带者中,仅储备成分和生物标志物成分显著:CogR每增加1个标准差与基线CDR-SB评分降低0.81倍相关(95%CI 0.72-0.92),CogB每增加1个标准差与CDR-SB降低0.60倍相关(95%CI 0.50-0.71)。
临床怎么用
- 认知储备评估可能有助于识别DIAD携带者中症状起病和进展风险较高的个体。
- 针对提高认知储备的干预措施可能对延缓DIAD临床发病和进展有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Cognitive reserve has been shown to modulate the onset and progression of Alzheimer disease (AD) symptoms. Although its role in sporadic AD is well-studied, how cognitive reserve influences the timing and progression of symptoms in dominantly inherited AD (DIAD) remains unclear. This study aimed to quantify cognitive reserve in DIAD carriers and test whether higher cognitive reserve is associated with later symptom onset and slower functional decline. METHODS: We analyzed data from the Dominantly Inherited Alzheimer's Network study. Cognitive reserve was modeled using a residual-based latent variable approach, decomposing cognitive performance into demographic (CogD), biomarker (CogB), and reserve or residual (CogR) components. Primary outcomes were age at clinical symptom onset (CDR >0) and longitudinal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SBs). Data were analyzed using Cox proportional hazards models and linear mixed-effects models, adjusting for estimated years from onset (EYO). RESULT: A total of 710 Dominantly Inherited Alzheimer Network (DIAN) participants were included in the analysis, comprising 271 non-DIAD carriers (nMC), 284 asymptomatic DIAD carriers (aMC), and 155 symptomatic DIAD carriers. In asymptomatic carriers, using a zero-inflation model adjusted for EYO showed that a 1 SD increase in the reserve component (CogR) was associated with a 4.06-fold increase in the odds of being clinically unimpaired (CDR-SB = 0; 95% CI 1.84-8.95). Similarly, a 1 SD increase in the demographic (CogD) and biomarker (CogB) components increased the odds of being CDR-SB = 0 by 2.60 (95% CI 1.10-6.16) and 5.16 (95% CI 2.00-13.33), respectively. Among symptomatic carriers, only the reserve and the biomarker components were significant. A 1 SD increase in CogR was associated with a 0.81-fold reduction in baseline CDR-SB score (95% CI 0.72-0.92), and a 1 SD increase in CogB was associated with a 0.60-fold reduction in CDR-SB (95% CI 0.50-0.71). DISCUSSION: Our findings indicate that higher cognitive reserve values are associated with delayed conversion to mild cognitive impairment and slower progression on clinical dementia rating scales. These findings suggest that cognitive reserve plays a protective role in modifying the clinical trajectory of genetically determined AD.
引用
- Llibre-Guerra JJ, Lu R, Clarens MF, et al. Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease. Neurology. 2026. PMID: 41950468. doi:10.1212/WNL.0000000000214804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。